Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clara G Chisari

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Environmental Research|July 3, 2020
CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onsetFrancesco Patti, Maria Fiore, Clara G Chisari, et al.
Frontiers in Neurology|April 27, 2019
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian CohortEmanuele D'Amico, Clara G Chisari, Sebastiano Arena, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|July 31, 2023
Retinal Thickness in Essential Tremor and Early Parkinson Disease: Exploring Diagnostic InsightsClaudio Terravecchia, Giovanni Mostile, Clara G Chisari, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 16, 2025
Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patientsClara G Chisari, Salvatore Lo Fermo, Salvatore Iacono, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 23, 2023
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)Clara G Chisari, Assunta Bianco, Vincenzo Brescia Morra, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Environmental Research|July 3, 2020
CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onsetFrancesco Patti, Maria Fiore, Clara G Chisari, et al.
Frontiers in Neurology|April 27, 2019
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian CohortEmanuele D'Amico, Clara G Chisari, Sebastiano Arena, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|July 31, 2023
Retinal Thickness in Essential Tremor and Early Parkinson Disease: Exploring Diagnostic InsightsClaudio Terravecchia, Giovanni Mostile, Clara G Chisari, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 16, 2025
Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patientsClara G Chisari, Salvatore Lo Fermo, Salvatore Iacono, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 23, 2023
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)Clara G Chisari, Assunta Bianco, Vincenzo Brescia Morra, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Pageof 2